| 4.96 0.2 (4.2%) | 06-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.19 | 1-year : | 7.23 |
| Resists | First : | 5.3 | Second : | 6.19 |
| Pivot price | 4.84 |
|||
| Supports | First : | 3.97 | Second : | 3.16 |
| MAs | MA(5) : | 4.86  |
MA(20) : | 4.7 |
| MA(100) : | 5.81 |
MA(250) : | 4.87 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 57.4 |
D(3) : | 63.4 |
| RSI | RSI(14): 52.5 |
|||
| 52-week | High : | 11.89 | Low : | 3.16 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CING ] has closed below upper band by 33.2%. Bollinger Bands are 70.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5 - 5.03 | 5.03 - 5.06 |
| Low: | 4.59 - 4.63 | 4.63 - 4.67 |
| Close: | 4.89 - 4.96 | 4.96 - 5.02 |
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
Fri, 26 Jun 2026
Cingulate, Inc. Actuals & Estimates (NASDAQ:CING) - TradingView
Fri, 26 Jun 2026
CING Forecast — Price Target — Prediction for 2027 - TradingView
Thu, 04 Jun 2026
FDA focuses on manufacturing for Cingulate CTx-1301, not safety - Stock Titan
Thu, 04 Jun 2026
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 - TMX Newsfile
Tue, 02 Jun 2026
Cingulate ADHD drug faces FDA data request, no safety concerns cited - Stock Titan
Tue, 02 Jun 2026
Cingulate Receives Complete Response Letter from FDA for CTx-1301 - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 30.5 (%) |
| Held by Institutions | 8.8 (%) |
| Shares Short | 1,960 (K) |
| Shares Short P.Month | 1,500 (K) |
| EPS | -4.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.58 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -69.7 % |
| Return on Equity (ttm) | -225.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.73 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.76 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -1.15 |
| PEG Ratio | 0 |
| Price to Book value | 3.13 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|